Trivalent Flu Vaccine and COVID-19

By August 3, 2020 No Comments
There should be an intense effort in determining more closely what are the underlying factors for severity of host response towards SARS-COV-2 infection. We know that some of these are genetic such as the blood group, but many are acquired.
A new study involving over 92,000 patients with COVID-19 in Brazil shows that the odds of severe disease, ventilatory support requirement, and death are reduced with a recent trivalent flu vaccine. This seems to indicate that these vaccines should be used as widely as possible to reduce the risk of severe COVID-19, especially among high-risk groups. (The study is published on the pre-print server medRxiv* in June 2020).
error: Content is Property of SMSbiotech